Not yet recruiting
A Study to Learn How Well People With Bronchiectasis Tolerate Continued Treatment With Verducatib After Earlier Studies (AIRTIVITY®-ON)
NCT07915219· Phase 3· Boehringer Ingelheim· Source
Contact: Boehringer Ingelheim
Recruiting
Finerenone in Patients Undergoing Transcatheter Aortic Valve Implantation With Heart Failure
NCT07575672· Phase 3· Second Affiliated Hospital, Zhejiang University, School of Medicine· Source
Contact: Yibing Shao, MD
Recruiting
A Clinical Trial of TQH3906 Capsules in Adult Patients With Moderate to Severe Plaque Psoriasis
NCT07724366· Phase 3· Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.· Source
Contact: Changyuan Wang, Doctor
Recruiting
Efficacy and Safety of Telitacicept in the Treatment of Refractory Rheumatoid Arthritis
NCT07796516· Phase 2· Peking University People's Hospital· Source
Contact: Qian Xing
Not yet recruiting
Clinical Trial of TQA3605 Tablet in Combination With Nucleos(t)Ide Analogues(NAs) Versus NAs Alone for the Treatment of Patients With Chronic Hepatitis B Virus Infection Who Have Undergone Treatment and Exhibit Low Viral Load or Poor Response
NCT07797231· Phase 3· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Source
Contact: Yongning Xin, doctor
Recruiting
Cardiopulmonary Exercise Testing-based High-intensity Interval Training For Improving Heart Failure With Preserved Ejection Fraction
NCT07693049· Peking University Third Hospital· Source
Contact: Yibing Shao (principal investigator)
Recruiting
Evaluation of Fecal Multi-target Biomarkers in the Screening of Digestive Tract Cancers
NCT07600125· Xijing Hospital· Source
Contact: wenli Li
Recruiting
TEAS Timing for Gastrectomy Recovery (TEAS-TIME Trial)
NCT07714980· The Affiliated Hospital of Qingdao University· Source
Contact: Hong Qi, MD
Not yet recruiting
Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma
NCT07569757· Phase 3· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Source
Contact: Yuping Zhong, Doctor
Recruiting
Single vs. Dual Antiplatelet Therapy in Patients Undergoing Percutaneous Intervention With DCB-only Strategy (KONG-FREEDOM-I)
NCT07587099· Gan Lijun· Source
Contact: Wei Xia
Not yet recruiting
A Prospective, Multicenter Exploratory Clinical Study on Consolidation Therapy With Tislelizumab Combined With Nintedanib for Limited-stage Small Cell Lung Cancer
NCT07485920· Phase 4· The Affiliated Hospital of Qingdao University· Source
Contact: wei chen
Recruiting
Phase II Trial of RC1416 Injection in Asthma
NCT07403487· Phase 2· Nanjing RegeneCore Biotech Co., Ltd.· Source
Contact: Han Wei
Recruiting
Phase II Study of RC1416 Injection in COPD
NCT07402551· Phase 2· Nanjing RegeneCore Biotech Co., Ltd.· Source
Contact: Yi Su
Recruiting
A Study to Test if Tenecteplase Helps People to Recover From an Acute Stroke When Given More Than 4.5 Hours After the Person Was Last Seen Well
NCT07361302· Phase 3· Boehringer Ingelheim· Source
Contact: Boehringer Ingelheim
Active, not recruiting
Clinical Trial of TQC2731 Injection in Patients With Chronic Sinusitis and Nasal Polyps
NCT07107256· Phase 3· Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.· Source
Recruiting
TQB2922 and TAS-102 Tablets for Injection With or Without Bevacizumab in Chemotherapy-failed RAS/BRAF Wild-type Advanced Colorectal Cancer
NCT07044908· Phase 1/2· Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.· Source
Contact: Xiaomei Xu, Master
Not yet recruiting
A Study to Predict Recompensation in Patients With Decompensated Cirrhosis Using Spleen Stiffness and Simple Blood Tests
NCT07087041· Beijing Friendship Hospital· Source
Contact: Bingqiong Wang, Dr
Recruiting
The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis
NCT06872892· Phase 3· Boehringer Ingelheim· Source
Contact: Boehringer Ingelheim
Recruiting
Phase II Trial of Iparomlimab/Tuvonralimab (QL1706) + XELOX in HER2-Negative, Low PD-L1 G/GEJ Adenocarcinoma
NCT06932068· Phase 2· Qilu Hospital of Shandong University· Source
Contact: xiaomei Xu
Not yet recruiting
Deep Sedation in Catheter Ablation of Atrial Fibrillation
NCT06836999· The First Affiliated Hospital of Dalian Medical University· Source
Contact: Bingong Li
Active, not recruiting
A Clinical Study of TQC2731 Injection in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
NCT06707883· Phase 2· Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.· Source
Recruiting
LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis
NCT06632457· Phase 3· Boehringer Ingelheim· Source
Contact: Boehringer Ingelheim
Recruiting
Long-term Impact of Inhaled Tobramycin for Pseudomonas Aeruginosa Eradication in Bronchiectasis (ERASE II)
NCT06760273· Shanghai Pulmonary Hospital, Shanghai, China· Source
Contact: Xue-dong Liu, MD
Recruiting
LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis
NCT06632444· Phase 3· Boehringer Ingelheim· Source
Contact: Boehringer Ingelheim
Recruiting
D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy Failure
NCT06300177· Phase 3· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Source
Contact: Mi Zhou, Master
Active, not recruiting
Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)
NCT06117774· Phase 3· Amgen· Source
Recruiting
Optimize First-line Treatment for AL Amyloidosis With t (11; 14)
NCT06192979· Jin Lu, MD· Source
Contact: Yuping Zhong
Recruiting
A Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple Myeloma
NCT06049290· Phase 1/2· Nanjing Leads Biolabs Co.,Ltd· Source
Contact: DongTao Meng
Active, not recruiting
A Clinical Trial of BAT4406F Injection in Patients With Neuromyelitis Optica Spectrum Disorders
NCT06044350· Phase 2· Bio-Thera Solutions· Source
Recruiting
Study of the Key Techniques of Prevention and Treatment of Osteoporotic Refracture
NCT05866029· Peking Union Medical College Hospital· Source
Contact: Qiang Li
Recruiting
Efficacy and Safety of a Half-dose Bolus of r-SAK Prior to Primary PCI in ST-elevation Myocardial Infarction
NCT05410925· Phase 4· The First Affiliated Hospital with Nanjing Medical University· Source
Contact: Yibing Shao, MD
Active, not recruiting
A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE
NCT05702034· Phase 3· Janssen Research & Development, LLC· Source
Active, not recruiting
Down Sizing Strategy (HANGZHOU Solution) vs Standard Sizing Strategy TAVR in Bicuspid Aortic Stenosis (Type 0)
NCT05511792· Second Affiliated Hospital, Zhejiang University, School of Medicine· Source
Active, not recruiting
A Study of NINLARO® in Chinese Adults With Multiple Myeloma
NCT05013190· Takeda· Source
Recruiting
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
NCT04973605· Phase 1/2· BeOne Medicines· Source
Contact: BeOne Medicines
Active, not recruiting
A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )
NCT04849728· Phase 3· Inventiva Pharma· Source
Enrolling by invitation
Efficacy and Safety of Almonertinib Combined With or Without Chemotherapy as an Adjuvant Treatment for Stage II-IIIA Non-small Cell Lung Carcinoma Following Complete Tumour Resection
NCT04762459· Phase 3· Chinese Academy of Medical Sciences· Source
Active, not recruiting
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer
NCT04691804· Phase 3· Jiangsu HengRui Medicine Co., Ltd.· Source
Active, not recruiting
A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder
NCT04658862· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
The Chinese Familial Alzheimer's Network
NCT03657732· Capital Medical University· Source
Contact: Lan Tan, Doctor
Recruiting
China Cognition and Aging Study
NCT03653156· Capital Medical University· Source
Contact: Lan Tan, Doctor